Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report

Table 1 Laboratory findings before treatment

Item	Value	Item	Value	Item	Value
AST	51 IU/L	BUN	16 mg/dL	HBsAg	negative
ALT	66 IU/L	Creatinine	0.68 mg/dL	Anti-HCV	positive
LDH	256 IU/L	UA	4.3 mg/dL	HCV RNA	6.4 logIU/mL
ALP	96 IU/L	Na	136 mEq/L	HCV genotype	2b
γ-GTP	88 IU/L	K	3.9 mEq/L	Anti-HIV	negative
T. Bil	1.2 mg/dL	Cl	104 mEq/L	Hyaluronic acid	37 ng/mL
TP	7.1 g/dL	WBC	5900/μL	AFP	7.4 ng/mL
Albumin	3.9 g/dL	RBC	477 × 10⁴/μL	PIVKA-II	32 mAU/mL
Amylase	83 IU/L	Hemoglobin	14.4 g/dL	NH₃	58 μg/dL
CPK	102 IU/L	Haematocrit	40.7 %	HbA1c	7.8 %
T.CHO	115 mg/dL	Platelets	15.6 × 10⁴/μL	CRP	0.1 mg/dL
TG	103 mg/dL	PT	100 %

AFP α-Fetoprotein, ALP alkaline phosphatase, BUN blood urea nitrogen, CPK creatine phosphokinase, CRP C-reactive protein, HbA1c haemoglobin A1c, LDH lactate dehydrogenase, PIVKA-II protein induced by vitamin K absence or antagonists-II, PT prothrombin time, RBC red blood cell count, T.Bil total bilirubin, T.CHO total cholesterol, TG triglyceride, TP total protein, UA uric acid, WBC white blood cell count